Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Astria Therapeutics Inc.

Astria Therapeutics, Inc. (($ATXS)) announced an update on their ongoing clinical study. Astria Therapeutics, Inc. is conducting a Phase 3 trial ti...

Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Astria Therapeutics, with a price target of $13.00. The com...

Astria Therapeutics (ATXS) Gets a Buy from LifeSci Capital

Investors will find the latest earnings reports, trade war updates, and business deals moving the stock market on Tuesday.


Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATXS	$12.51	-0.79%	1.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATXS	$12.51	-0.8%	1.22M
3
4
5
6

ATXS

ATXS

Dividend Overview

Get Astria Therapeutics Inc. Data in Excel

Get Astria Therapeutics Inc. Data in Excel